Moreover, it has been demonstrated that the expression of ACE1, which cleaves bradykinin into the metabolites bradykinin1-7 but not bradykinin1-5, as shown recently (Souza-Silva et al., 2022), is higher in severe COVID-19 patients (Akbari et al., 2022), representing one way by which bradykinin level is decreased in the plasma of SARS-CoV-2 infected individuals in comparison with the control group. The gene discussed is ACE; the disease is COVID-19.